Virtual Library
Start Your Search
Hisashi Oishi
Author of
-
+
EP1.18 - Treatment of Locoregional Disease - NSCLC (ID 208)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Treatment of Locoregional Disease - NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.18-13 - Review of Preoperative Examination (Now Available) (ID 1351)
08:00 - 18:00 | Author(s): Hisashi Oishi
- Abstract
Background
Before lung resection, it is necessary to perform various preoperative examinations to determine the indication for surgery. In our department, lung blood flow scintigraphy is performed on all cases scheduled for lung resection, and predicted post operation (ppo)%FEV1 and ppo%DLCO, are calculated based on lung function tests and scheduled surgery. Both have a cut-off value of 40%, and if the case has less than 40%, change to surgery with less lung volume loss.
However, the large number of cases have no difference between left and right lung blood flow ratios. Even if the difference is large, almost all cases have organic lung abnormalities which are detected by CT easily. In addition, even if there is a large dissociation in the left-right difference in pulmonary blood flow, it is very rare that the predicted value after surgery is less than 40% in normal respiratory function patients. In recent years, most institutions do not perform pulmonary blood flow scintigraphy as preoperative examination, and it may be necessary to examine the significance of lung blood flow scintigraphy as preoperative examination.
Method
Of the cases in which lung blood flow scintigraphy was performed as a preoperative examination for lung resection in our department from January 2010 to December 2018, we selected the cases who has the blood flow ratio between the left and right lungs has more than doubled difference and doesn’t have detectable organic abnormality and history of lung resection.
Result
Nineteen out of 1570 cases were extracted. The blood flow of the right lung was more than twice that of the left lung in 18 cases. 19 cases have 12 men and the average age is 73.6 ± 6.9. There were 13 cases undergoing planned surgery, 3 cases that could not be resected due to the progress of the tumor, 1 case refusing the operation, and only 2 cases changed treatment based on the result of scintigraphy. One case treated by radiation therapy and another was treated by PDT.
Conclusion
It is suggested that lung blood flow scintigraphy may not be necessary in cases who have normal pulmonary function and have no organic abnormalities.
-
+
P2.09 - Pathology (ID 174)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Pathology
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.09-09 - EGFR Is Highly Mutated in Lung Adenocarcinoma Patients with History of Breast Cancer (ID 2210)
10:15 - 18:15 | Author(s): Hisashi Oishi
- Abstract
Background
EGFR gene mutation has been reported to be frequent in the patients with specific clinical features such as female, adenocarcinoma, and East-Asian ethnicity. The mutation rate in lung adenocarcinoma is approximately 50% in Japan. Currently, the molecular mechanism which cause EGFR mutation has not been clarified. If the EGFR mutation in lung adenocarcinoma correlates with specific type of malignancy in the other organ, it could be a clue to find a mechanism which promote carcinogenesis of lung adenocarcinoma. In the current study, we focused on breast cancer.
Method
Patients with lung adenocarcinoma who underwent pulmonary resection in our hospital from January 2011 to December 2018 were analyzed. We retrospectively reviewed clinical information such as past illness, radiological findings, pathological diagnosis, and EGFR mutation status. Correlation was tested by chi-square test and p value of less than 0.05 was regarded as statistically significant.
Result
A total of 21 patients of lung adenocarcinoma had history of treatment for breast cancer. All patients were female. Among them, EGFR mutation was detected in 20 patients (95%). One patient who were negative for EGFR mutation had history of not only breast cancer but also cervical cancer of uterus and gastrointestinal stromal tumor, and developed angiosarcoma of the skin. Detected EGFR mutation types in 20 patients were as follows; deletion in exon 19 for 9 patients, L858R for 7 patients G719X for two patients, and L861Q for one patient. One patient showed multiple mutation (G719X and L861). In the same period, among 203 lung adenocarcinoma patients without other organ malignancy, 115 showed EGFR mutation (56.7%). There was significant difference in EGFR mutation rate between breast cancer group and no malignancy group (p=0.00058).
Conclusion
Patients of lung adenocarcinoma with history of breast cancer showed extremely high positive rate for EGFR mutation in Japan, suggesting underlying common oncogenic molecular mechanism between lung adenocarcinoma and breast cancer. Elucidation of the mechanism may contribute to the diagnosis and treatment of carcinogenesis of breast cancer and lung cancer.
